Top Markets
#1 TENDIES TENDIES +43.22%
#2 GEKKO GEKKO +43.17%
#3 Pons Pons +40.37%
#4 ADO Protocol ADO Protocol +38.68%
#5 Helium Helium +28.36%
#6 Prom Prom +24.56%
#7 龙虾 (Lobster) 龙虾 (Lobster) +20.59%
#8 o1.exchange o1.exchange +17.90%
#9 Main Street Yield Main Street Yield +17.48%
#10 Nillion Nillion +17.32%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Rank in Stocks #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Share Price
$1.72
Last synced: 2026-08-28
Market Cap
$981.92M
Change (1 day)
-1.68%
Change (1 year)
-41.83%
Country
CN
Trade CARsgen Therapeutics Holdings Limited (2171)

Category

Healthcare
Dividend history for CARsgen Therapeutics Holdings Limited (2171)
CARsgen Therapeutics Holdings Limited (stock symbol: 2171) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for CARsgen Therapeutics Holdings Limited (2171) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH